Intelligence · Patents
Patents expiring in 2026
Annual patent cliff calendar for 2026 — US pharmaceutical patents by expiration date.
- Patents
- 360
Quick answer
360 indexed pharmaceutical patents have expiration dates in 2026. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 7097841
Ferritin fusion proteins for use in vaccines and other applications
granted -
US 7098345
Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
granted -
US 7098330
Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors
granted -
US 7098364
Phenylethanolamine compounds as β2-receptor agonists, and methods of use and preparation thereof
granted -
US 7098306
Method and compositions for treating hepatocellular cancer
granted -
US 7098197
Phosphonate compounds
granted -
US 7098191
Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
granted -
US 7098025
Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
granted -
US 7097998
Aβ42 lowering agents
granted -
US 7097972
Method and composition for regulating apoptosis
granted -
US 7097991
Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
granted -
US 7097856
Dendrimeric support or carrier macromolecule
granted -
US 7102059
DNA molecules and polypeptides of Pseudomonas syringae Hrp pathogenicity island and their uses
granted -
US 7101557
Combined tissue factor methods for coagulation and tumor treatment
granted -
US 7101846
Methods and compositions for optimization of oxygen transport by cell-free systems
granted -
US 7101909
Calcium channel drugs and uses
granted -
US 7101867
Benzofuran derivatives, their production and use
granted -
US 7101548
Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
granted -
US 7101899
5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
granted -
US 7101547
Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
granted -
US 7101932
Method for the preparation of 1-benzotriazolyl carbonate esters of poly (ethylene glycol)
granted -
US 7101863
Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative
granted -
US 7101852
Composition and method for treatment and prevention of restenosis
granted -
US 7101541
Utilization of non-viral sequences for minus-strand DNA transfer and gene reconstitution
granted -
US 7101964
Intermediate for preparing glycopeptide derivatives
granted -
US 7105514
Substituted indolealkanoic acids
granted -
US 7105169
Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
granted -
US 7105641
MCP-1 receptor antibodies
granted -
US 7105546
Acyclic and cyclic amine derivatives
granted -
US 7105183
Chlorite in the treatment of neurodegenerative disease
granted -
US 7105156
Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells
granted -
US 7105695
Synthesis of combretastatin A-2 prodrugs
granted -
US 7105643
Monoclonal antibodies specific for crack cocaine metabolites, a cell line producing the same, and crack cocaine conjugates
granted -
US 7105572
Stable emulsion compositions
granted -
US 7105558
Gastrin and cholecystokinin receptor lignads (iv)
granted -
US 7105561
Use of etodolac for the treatment of prostate cancer
granted -
US 7105560
Use of etodolac in the treatment of multiple myeloma
granted -
US 7105496
Methods and compositions for inhibiting angiogenesis
granted -
US 7105488
G protein-coupled receptor antagonists
granted -
US 7105171
Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
granted -
US 7105170
Latent human tuberculosis model, diagnostic antigens, and methods of use
granted -
US 7105330
Human plasma hyaluronidase
granted -
US 7109188
Methods and compositions for treating atheroma, tumors and other neoplastic tissue
granted -
US 7108975
Atlastin
granted -
US 7109245
Vasoconstrictor cannabinoid analogs
granted -
US 7108986
Glypican-1 in human breast cancer
granted -
US 7109215
Compounds possessing neuronal activity
granted -
US 7109303
Modified cytokines for use in cancer therapy
granted
Frequently asked questions
How many pharma patents expire in 2026?
360 published patents in our USPTO index have expiration dates falling in calendar year 2026.